ALK and anaplastic large cell lymphoma: In another study, pediatric ALCL patients could be stratified into different risk groups by a combination of MDD (from PB or BM) and anti-ALK antibody titre: PFS was 28% for high-risk patients and 93% for the low-risk group [59].